References
- Afzal M., Kafetzakis E. M. Assessment of perhexiline maleate in angiographically proven intractable angina: a double-blind trial. American Heart Journal 1978; 96: 350–354
- Amoah A. G. B., Gould B. J., Parke D. V., Lockhart J. D. F. Further studies on the pharmacokinetics of perhexiline in the human. Xenobiotica 1986; 16: 63–68
- Boxenbaum H. G., Jodhka G. S., Ferguson A. C., Riegelman S., MacGregor T. R. The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man. Journal of Pharmacokinetics and Biopharmaceutics 1974; 2: 211–237
- Cooper R. G., Evans D. A. P., Whidley E. J. Polymorphic hydroxylation of perhexiline maleate in man. Journal of Medical Genetics 1984; 21: 27–33
- Cooper R. G., Harper G., Price A. H., Evans D. A. P., Lockhart J. D. F. Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids, by gas chromatography-electron capture detection. Journal of Chromatography, Biomedical Applications 1986; 381: 305–315
- Cooper R. G., Evans D. A. P., Price A. H. Studies on the metabolism of perhexiline in man. European Journal of Clinical Pharmacology 1987; 32: 569–576
- Evans D. A. P., Harmer D., Downham D. Y. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. Journal of Medical Genetics 1983; 20: 3212–3219
- Leeson G. A., Zeiger A. V., Lang J. R., Wright G. J. Metabolic fate of perhexiline-14C maleate. Federation Proceedings 1969; 28: 798
- Milburn P., Smith R. L., Williams R. T. Biliary excretion of foreign compounds. Biphenyl, stilboestrol and phenolphthalein in the rat; molecular weight, polarity and metabolism as factors in biliary excretion. Biochemical Journal 1967; 105: 1275–1281
- Nick J., Dudognon P., Escourolle R., Bakouche P., Nicholle M. H., Reignier A., Hauw J. J., Ermidou S., Pollet S., Baumann M., Singlas E., Levy J. Neurological disorders and perhexiline maleate therapy. Clinical study of 10 cases. Neuropathological, pharmacokinetic and biochemical studies. Reviews in Neurology 1978; 134: 103–114
- Oates N. S., Shah R. R., Idle J. R., Smith R. L. Genetic pohymorphism of phenofrmin 4-hydroxylation. Clinical Pharmacology and Therapeutics 1982; 32: 81–89
- Oates N. S., Shah R. R., Idle J. R., Smith R. L. The metabolic disposition of the stereoisomers of perhexiline maleate and the influence of oxidation phenotype. British Journal of Clinical Pharmacology 1984; 18: 307P
- Pessayre D., Birchara M., Feldmann G., Degott C., Potet F., Benhamou J. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979; 76: 170–177
- Shah R. R., Oates N. S., Idle J. R., Smith R. L., Lockhart J. D. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. British Medical Journal 1982; 284: 295–299
- Smith R. L. Species differences in the biliary excretion of drugs. Proceedings of the European Society for the Study of Drug Toxicity 1970; 11: 19–32
- Smith R. L. The excretory function of bile. Chapman and Hall, London 1973; 76–93
- Tse F. L. S., Ballard F., Skinn J. Estimating the fraction re-absorbed in drugs undergoing enterohepatic circulation. Journal of Pharmacokinetics and Biopharmaceutics 1982; 10: 455–461
- Wright G. J., Zeiger A. V., Lemieux R. E., McRoberts E., Carr A. A., Leeson G. A., Lang J. F. Perhexiline maleate; characterisation and identification of metabolic products. Merrell Research Centre, Merrell National Laboratories, Division of Richardson-Merrell Inc., Cincinnatti, Ohio 1972
- Wright G. J., Leeson G. A., Zeiger A. V., Lang J. F. The absorption, excretion and metabolism of perhexiline maleate by the human. Postgraduate Medical Journal 1973; 49(Supplement 3–8)15